Antibiotic therapy in necrotizing soft tissue infections: a narrative review of the greater Paris SURFAST consortium - Summary - MDSpire

Antibiotic therapy in necrotizing soft tissue infections: a narrative review of the greater Paris SURFAST consortium

  • By

  • Caroline Charlier

  • Bérénice Souhail

  • Stéphane Dauger

  • Paul-Louis Woerther

  • Alexandre Bleibtreu

  • Marion Caseris

  • Olivier Chosidow

  • Chloé Bertolus

  • Camille Hua

  • Gentiane Monsel

  • Asmaa Tazi

  • Tomas Urbina

  • Benjamin Vérillaud

  • Philippe Montravers

  • Raphaël Lepeule

  • Nicolas de Prost

  • October 10, 2025

  • 0 min

Share

Objective:

To present practice recommendations for antibiotic management of necrotizing soft tissue infections (NSTIs) and review the supporting evidence, focusing on specific types of NSTIs.

Key Findings:
  • NSTIs are rare but life-threatening, with a mortality rate of 10% to 30%; early surgical debridement is essential alongside antibiotic therapy.
  • Most NSTIs are polymicrobial, with common pathogens including streptococci and Enterobacterales.
  • Empiric antibiotic therapy should be guided by risk factors for ESBL-E and MRSA infections.
Interpretation:

Standardizing antibiotic management for NSTIs is crucial due to the heterogeneous practices currently observed, and the SURFAST consortium aims to improve outcomes through consensus guidelines by addressing these variations.

Limitations:
  • Data on optimal antibiotic treatment for NSTIs is limited and primarily based on observational studies, which may not reflect all clinical scenarios.
  • The consensus recommendations may not be universally applicable due to regional variations in pathogen prevalence and local healthcare practices.
Conclusion:

The establishment of a multidisciplinary approach and consensus guidelines is essential for improving the management of NSTIs and reducing associated morbidity and mortality, while ongoing research is needed to address existing gaps.

Original Source(s)

Related Content